공고 • Sep 21
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent CanaQuest Medical Corp. announced it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects. The formulated product is branded as Mentabinol®?, which addresses various psychiatric disorders. Acute THC consumption can trigger worrying thoughts in vulnerable individuals. Mentabinol®? - Formulation utilizing pharmaceutical-grade botanical extract, L-theanine, and THC molecules extracted from cannabis. The Scientific Difference - based on pre-clinical trial results at Western University. For many users, THC causes: Memory impairment and possible long-term cognitive side effects, Depression-like and schizophrenia-related symptoms, Anxiety and hyperactive activity, Schizophrenia due to gene vulnerability. Application of Mentabinol®? has demonstrated in pre-clinical trials: Reversal of depression-like and schizophrenia-related symptom effects, Blockage of memory impairment, hyperactive activity, and gene vulnerability. The discovery was made by a research team led by Dr. Steven Laviolette, a professor, and neuroscientist at Western University with decades of experience in the fields of mental health and cannabinoids. Western University researchers believe this formulation may mitigate this type of harm to chronic cannabis users. The team also concluded that their research provides evidence for combining the THC-based formulations with L-theanine to make them safer for both recreational and medicinal use. Physicians, psychiatrists, and healthcare practitioners, interested in joining network, as well as institutions, clinics, and pharmacies, can register via Join network. 공고 • Dec 10
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD CANAQUEST MEDICAL CORP announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control. Highlights derived from the Study are as follows: The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University. These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients). CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years. 공고 • Oct 27
CanaQuest Medical Corp. announced a financing transaction CanaQuest Medical Corp. announced that it will receive $2,000,000 in a round of funding on October 26, 2022. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. 공고 • Sep 09
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US CanaQuest Medical Corp. announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international export. Proprietary Formulation - IP protected, International Patents filed, and Pre-clinical Trial results - published in peer-reviewed European Journal of Neuroscience (Oct. 2020). New Pathway Discovery - molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials. Mentanine® was developed by Dr. Steven Laviolette, a neuroscientist and scientific veteran with decades of research experience in the field of mental health and cannabinoids. Dr. Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. 공고 • Mar 12
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre CanaQuest Medical Corp. announced its new partnership with the Canadian Cannabis Dispute Resolution Centre to assist different levels of government, the private sector, industry-specific organizations and associations. The CCDRC/CanaQuest partnership will serve to raise global awareness. The common theme of all education relates to conflict resolution, which can be mitigated through education. A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data and published research papers of Dr. Steven Laviolette and his 13-person team at Western University in Canada. 공고 • Feb 03
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc CANAQUEST MEDICAL CORP announced a new production and distribution agreement with PurCann Pharma and SiliCycle Inc. This agreement facilitates CanaQuest’s planned production, distribution and global export of Mentanine® and Mentabinol® formulations, through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License from Health Canada under the Cannabis Act. Initial sales are anticipated within 16 weeks after funding. 
